Half-year report · Q2
4886.TEDINET S100UNSK
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥32.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥62.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥88.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥90.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥91.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥24.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥28.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥64.2bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥61.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.7bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥90.36 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥266.51 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.93 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 72.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥151m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥113m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥177m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥108m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥80m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥27m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥585m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥44m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥28.4bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥31.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥31.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 456
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 2204000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0777 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1877000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0662 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1658000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0584 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 1347000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0474 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 1100000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0387 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 803000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0283 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 579000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0204 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 553000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0195 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 539000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0190 | |
| Number of shares held | CurrentQuarterInstant | 13628000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.4804 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2197300 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 28343800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 283438 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 22099 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 30563199 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 283438 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 2197300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 2197300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0718 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 2197300 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 2197300 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0718 | |
| Cash and deposits | Prior1YearInstant | 13738000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 12705000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 15579000000 | JPY |
| Accounts receivable trade | CurrentQuarterInstant | 15591000000 | JPY |
| Short term investment securities | Prior1YearInstant | 3500000000 | JPY |
| Short term investment securities | CurrentQuarterInstant | 1000000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 12578000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 11697000000 | JPY |
| Work in process | Prior1YearInstant | 466000000 | JPY |
| Work in process | CurrentQuarterInstant | 590000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 7358000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 8440000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |